Serum Biomarker HE4 During IVF Treatment (FHE4)
|ClinicalTrials.gov Identifier: NCT01576744|
Recruitment Status : Unknown
Verified June 2012 by Antti Perheentupa, Turku University Hospital.
Recruitment status was: Active, not recruiting
First Posted : April 12, 2012
Last Update Posted : June 4, 2012
Human epididymal secretory protein 4 (HE4) is a new biomarker for ovarian cancer. The effect of IVF stimulation will be evaluated in order to see whether severe hormonal changes in the gonadotrophin and steroid status affect the serum levels of this marker. Findings will be compared to serum concentrations of CA-125, which is currently the most often used marker for ovarian cancer.
The intention is to determine the serum concentration of HE4 and CA-125 in serial samples in 20 women undergoing IVF stimulation. Samples will be taken following GnRH agonist suppression, 2-3 times during FSH stimulation, at ovum pick up and two weeks following embryo transfer at the time of the hCG-test. The ovarian follicle count and the serum estradiol concentrations are recorded throughout the treatment. The serum biomarker HE4 is expected to ba a stable marker, which does not respond significantly to hormonal stimulation.
|Condition or disease|
|IVF Treatment Human Epididymal Secretory Protein E4|
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||Serum Concentration of HE4, a New Marker for Ovarian Cancer, Changes Little Throughout IVF Stimulation|
|Study Start Date :||March 2010|
|Estimated Primary Completion Date :||June 2012|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01576744
|Department of Obstetrics and Gynecology, Turku University Hospital|
|Turku, Finland, 20520|
|Principal Investigator:||Antti H Perheentupa, MD, PhD||Department of Obstetrics and Gynecology, Turku University Hospital|